Microbubbles-Ultrasound Contrast Agents Market

1. The global microbubbles/ultrasound contrast agents market will grow at a CAGR of 25.2% from 2018 to 2024 to reach USD 1,584.5 million by 2024, majorly driven by “various advancements in ultrasound technologies, benefits of ultrasound over alternative technologies, favorable reimbursement policies for contrast enhanced procedures in the U.S., increase in demand for diagnostics & image guided procedures, and growing aging population and subsequent rise in the prevalence of chronic diseases,”Meticulous Research™ noted in a press release today. The report further notes that, ”rising research for the use of microbubbles as an effective media for drug delivery and gene therapy, and related positive outcomes are expected to provide significant opportunities in this market. However, complexity in contrast enhanced ultrasound (CEUS) procedures, lack of training and financial resources, and side effects related to ultrasound contrast agents hinder the growth of the market to some extent.” The report also states that, the molecular imaging commanded the largest share in this market in 2017, owing to “rising adoption of microbubbles in echocardiography procedures with advancement in molecular and ultrasound technologies.” Request Sample Report Geographically, North America held the largest share in this market, due to “rising aging population, increasing number of chronic diseases, well- established healthcare system with wide spread suppliers & distributors, higher adoption of innovative technologies, rising technological advancements in healthcare, and higher healthcare spending in the region, especially in the U.S. However, Asia-Pacific region to witness a rapid growth with rising healthcare spending, improving healthcare infrastructure, rising living standards with increasing income of middle class population, rising healthcare awareness, growing aging population and subsequently rising prevalence of chronic diseases in the Asian countries.” The key players in the global microbubbles/ultrasound contrast agents market are Lantheus Holdings, Inc. (U.S.), Bracco (Italy), GE Healthcare (U.S.), Daiichi Sankyo Company, Limited (Japan), and nanoPET Pharma GmbH (Germany). Scope of the report: Scope of the report: Market by Therapeutic Area: Market by Therapeutic Area: •Cardiovascular diseases •Renal and associated diseases

2. •Others Market by Application: Market by Application: •Molecular imaging •Gene therapy •Drug delivery •Stem cells delivery Market by Geography: Market by Geography: •North America •Europe •Asia-Pacific (APAC) •Rest of the World